Rudolph, Annette
Dahmke, Hendrike
Kupferschmidt, Hugo
Burden, Andrea
Weiler, Stefan http://orcid.org/0000-0003-1087-7597
Funding for this research was provided by:
University of Zurich
Article History
Received: 24 April 2020
Accepted: 11 August 2020
First Online: 6 January 2021
Compliance with ethical standards
:
: SW is a member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties. AR, HD, AMB, and HK have no conflicts of interest to declare. The authors used data from the VigiBase, the WHO global database of individual case safety reports (ICSRs) as a source of information. However, the conclusions do not represent the opinion of the UMC or the WHO.
: The data for this work were obtained from the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. Data from spontaneous reporting are inhomogeneous because of different reporting policies worldwide and are vulnerable to underreporting and reporting bias. The information contained in this work related to the Pharmacovigilance Database is therefore not homogeneous.